Effect of doxycycline versus placebo on clinical outcomes in patients with ischemic stroke

Effect of doxycycline versus placebo on clinical outcomes in patients with ischemic stroke: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N432

Enrollment

Registered

2022-06-28

Start date

2022-08-06

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke. Cerebral infarction

Interventions

Intervention 1: Intervention group: Routine treatment plus doxycycline capsule 100 mg every 12 hours for 7 days. Intervention 2: Control group: Routine treatment plus placebo starch) capsule every 12

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Age 18 to 85 years Ischemic stroke in the last 24 hours

Exclusion criteria

Exclusion criteria: Pregnancy or lactation History of ischemic stroke

Design outcomes

Primary

Measure	Time frame
Neurological dysfunction. Timepoint: Before intervention, one week, one and three months later. Method of measurement: Using the NIH Stroke Scale (NIHSS).;Functional dysfunction. Timepoint: Before intervention, one week, one and three months later. Method of measurement: Using the modified Rankin Scale (mRS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Aminian

Hamedan University of Medical Sciences

zahra.amn95@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026